文献速递肝病消化道肿瘤与早癌

直接抗病毒药物治疗丙型肝炎治愈后肝细胞癌发病率的纤维化分期特异性:系统综述与Meta分析

Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-05-05

该研究系统检索2014年1月1日至2020年12月31日数据库,纳入31项肝硬化研究(27,711例,平均随访2.1年)和11项非肝硬化研究(32,123例,平均随访2.6年),评估直接抗病毒药物获得持续病毒学应答后肝细胞癌发病率。肝硬化患者汇总发病率为2.99/100人年(95%CI 2.52-3.54;I²=75%),非肝硬化患者为0.47/100人年(95%CI 0.32-0.70;I²=71%),F3纤维化患者为0.63/100人年(95%CI 0.34-1.20;I²=0%)。结论认为肝硬化患者发病率高但可能随随访延长而下降,非肝硬化及F3纤维化患者发病率低于成本效益筛查阈值,F3纤维化研究间无显著异质性,强烈提示可能无需筛查。

要点

  • 肝硬化患者SVR后HCC汇总发病率为2.99/100人年,非肝硬化患者为0.47/100人年。
  • F3纤维化患者HCC发病率为0.63/100人年,研究间异质性I²=0%。
  • 肝硬化患者随访<1年发病率最高(6.17/100人年),≥3年降至1.83/100人年。

核心结论

  • 肝硬化患者SVR后HCC汇总发病率很高(2.99/100人年),但可能随SVR后时间延长而下降。
  • 非肝硬化包括F3纤维化患者HCC发病率低于与成本效益筛查相关的阈值。
  • F3纤维化患者研究间缺乏异质性,提供了HCC筛查可能不需要的强证据。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Web of Science、Embase和Cochrane Library(2014年1月1日至2020年12月31日)。
  • 纳入直接抗病毒药物治疗后获得持续病毒学应答的成人丙型肝炎患者中评估HCC发病率或结局的研究,按肝硬化状态分组。
  • 纳入31项肝硬化研究(27,711例,平均随访2.1年)和11项非肝硬化研究(32,123例,平均随访2.6年)。
  • 采用随机效应模型汇总估计,并进行亚组、敏感性和Meta回归分析评估异质性。

主要发现

  • 肝硬化患者HCC发病率为2.99/100人年(95%CI 2.52-3.54;I²=75%)。
  • 非肝硬化患者HCC发病率为0.47/100人年(95%CI 0.32-0.70;I²=71%)。
  • F3纤维化患者HCC发病率为0.63/100人年(95%CI 0.34-1.20;I²=0%)。
  • 肝硬化患者中,随访<1年的研究HCC发病率最高为6.17/100人年(95%CI 3.73-10.19),随访1-2年为2.75/100人年(95%CI 2.48-3.06),2-3年为2.90/100人年(95%CI 1.90-4.44),≥3年为1.83/100人年(95%CI 0.88-3.80)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatitis C virus (HCV) eradication with direct-acting antivirals reduces hepatocellular carcinoma (HCC) risk. Pooled HCC incidence rates by cirrhosis status and fibrosis stage have not been estimated using meta-analysis. METHODS: We searched PubMed, Web of Science, Embase, and Cochrane Library from January 1, 2014 to December 31, 2020 to identify studies assessing HCC incidence or outcomes by cirrhosis status, in adults with HCV who achieved sustained virologic response (SVR) after direct-acting antivirals. Pooled estimates were obtained using random-effects modeling. Subgroup, sensitivity, and meta-regression analyses were performed to evaluate heterogeneity. RESULTS: We included 31 studies involving 27,711 patients with cirrhosis (mean follow-up, 2.1 years) and 11 studies involving 32,123 patients without cirrhosis (mean follow-up, 2.6 years). HCC incidence was 2.99/100 person-years (95% confidence interval [CI], 2.52-3.54; I2 = 75%) in patients with cirrhosis, 0.47/100 person-years (95% CI, 0.32-0.70, I2 = 71%) in patients without cirrhosis, and 0.63/100 person-years (95% CI: 0.34-1.20, I2 = 0%) in stage 3 (F3) fibrosis. Among patients with cirrhosis, HCC incidence was highest in studies with <1 year of follow-up (6.17/100 person-years [95% CI, 3.73-10.19]) and progressively lower in studies with longer follow-up (1-2 years: 2.75/100 person-years [95% CI, 2.48-3.06]; 2-3 years: 2.90/100 person-years [95% CI, 1.90-4.44]; ≥3 years: 1.83/100 person-years [95% CI, 0.88-3.80]). CONCLUSION: Pooled HCC incidence after SVR in patients with cirrhosis was very high (2.99/100 person-years) but may be declining as longer time accrues after SVR. In patients without cirrhosis, including F3 fibrosis, HCC incidence was lower than thresholds associated with cost-effective HCC screening. In patients with F3 fibrosis, the lack of between-study heterogeneity provides strong evidence that HCC screening may not be warranted.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kim NJ, Vutien P, Cleveland E, et al. Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022. PMID: 35525392. doi:10.1016/j.cgh.2022.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。